SEARCH

SEARCH BY CITATION

References

  • 1
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 2
    Berenguer M, Ferrell L, Watson J c HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 3
    Neumann U, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830836.
  • 4
    Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852858.
  • 5
    Rosen H, Prieto M, Casanovas-Taltavull et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38: 460469.
  • 6
    Wall W, Khakhar A. Retransplantation for recurrent hepatitis C: the argument against. Liver Transpl 2003; 9: S73S78.
  • 7
    Wiesner R, Sorrell M, Villamil F. International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1S9.
  • 8
    Burak KW, Kremers WK, Batts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362369.
  • 9
    Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549557.
  • 10
    Rifai K, Sebagh M, Karam V et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004; 41: 446453.
  • 11
    Sheiner P, Schwartz M, Mor E et al. Severe and multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 3034.
  • 12
    Rosen H, Shackleton C, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 14531457.
  • 13
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 14
    Rosen HR, Chou S, Corless CL et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721726.
  • 15
    Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 16
    Berenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756763.
  • 17
    Garcia-Retortillo M, Forns X et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699707.
  • 18
    Shiffman M, Stravitz R, Contos M et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10: 12481255.
  • 19
    Russo M, Galanko J, Beavers K, Fried M, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10: 340346.
  • 20
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE, Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 13961399.
  • 21
    Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966971.
  • 22
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12821288.
  • 23
    Martin P, Busuttil RW, Goldstein RM et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 12581262.
  • 24
    Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 25
    Fisher RA, Stone JJ, Wolfe LG et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463472.
  • 26
    Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005; 5: 406411.
  • 27
    Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 5257.
  • 28
    Gane E, Naoumov N, Qian K et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167177.
  • 29
    Belli L, Alberti A, Vangeli M, Airoldi A, Pinzello G. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003; 9: 201202.
  • 30
    Filipponi F, Callea F, Salizzoni M et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 14881495.
  • 31
    Brillanti S, Vivarelli M, De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884888.
  • 32
    Abdelmalek M, Firpi R, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199207.
  • 33
    Bizollon T, Pradat P, Mabrut J-Y et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant; 5: 19091913.
  • 34
    Saab S, Kalmaz D, Gajjar N et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859867.
  • 35
    Stravitz R, Shiffman M, Sanyal A et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850858.
  • 36
    Dumortier J, Scoazec J, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 37
    Narayanan Menon KV, Poterucha JJ, El-Amin OM et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623629.
  • 38
    Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 39
    Lavezzo B, Franchello A, Smedile A et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247252.
  • 40
    Firpi R, Abdelmalek M, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 41
    Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642650.
  • 42
    Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289298.
  • 43
    Everson G, Trotter J, Forman L et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology; 42: 255262.
  • 44
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 45
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 46
    Forns X, Navasa M, Rodes J. Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004; 40: 498.
  • 47
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350355.
  • 48
    Torriani F, Rodriguez-Torres M, Rockstroh J et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 49
    Bartosch B, Bukh J, Meunier JC et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003; 100: 1419914204.
  • 50
    Lavillette D, Morice Y, Germanidis G et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79: 60236034.
  • 51
    Krawczynski K, Alter M, Tankersley D et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822828.
  • 52
    Davis G, Nelson D, Terrault N et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941949.
  • 53
    Willems B, M E, Marotta P et al. Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation. J Hepatol 2002; 36: S96A.
  • 54
    Shergill A, Khalili M, Bollinger K, Roberts J, Ascher N, Terrault N. Applicability, tolerability and efficacy of preemptive anviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118124.
  • 55
    Singh N, Gayowski T, Wannstedt CF et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 8286.
  • 56
    Sheiner P, Boros P, Klion F et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831838.
  • 57
    Sugawara Y, Makuuchi M, Matsui Y et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 13081311.
  • 58
    Terrault N. Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 2005; 3: 81258131.
  • 59
    Gane E, Lo S, Portmann B, Lau J, Naoumov N, Williams R. A randomized study of the safety and efficacy of ribavirin versus interferon montherapy for recurrent HCV infection in liver transplant recipients. Hepatology 1998; 27: 14031407.
  • 60
    Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 10841089.
  • 61
    Giostra E, Kullak-Ublick G, Keller W et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17: 169176.
  • 62
    Mukherjee S, Lyden E, McCashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20: 198203.
  • 63
    Bizollon T, Ahmed S, Radenne S et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 64
    Berenguer M, Prieto M, Palau A et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 12071212.
  • 65
    Gopal DV, Rabkin JM, Berk BS et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181190.
  • 66
    Neff G, Montalbano M, O'Brien C et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 67
    Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905915.